Recently, Gilead Sciences has received Congressional scrutiny for its $1,000 a pill price tag on hepatitis C drug Sovaldi. The typical 12-week drug regimen of Sovaldi costs $84,000, but some patients require the drug for a longer period of time.
Sens. Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa) sent a letter to Gilead seeking an explanation for Sovaldi’s hefty price tag. “Given the impact Sovaldi’s cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug,” the senators wrote in the letter.
The Morning Consult survey revealed 82 percent of Americans believe charging $1,000 a pill is “unacceptable.”
The poll was sponsored by the Campaign for Sustainable Rx Pricing. The survey was conducted from July 9 to July 11, among a national sample of likely voters.
More Articles on Sovaldi:
FDA Approves Second Drug in Two Weeks to Treat Hepatitis C
Hepatitis C Drug Costs More Than 1K a Pill
Sovaldi Drug Sales Could Reach $9B in First Year
